telomerase: 540-548 peptide vaccine
Biologicalexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2000 (NCT00069940)
Timeline
Indications
Mechanism of action
- Telomerase reverse transcriptaseImmunity, active
TERT immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- telomerase: 540-548 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00079157 | Phase 1 | Feb 1, 2004 | National Cancer Institute (NCI), University of Pennsylvania |
| NCT00021164 | Phase 2 | May 1, 2001 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00069940 | Phase 1 | Dec 1, 2000 | Harvard University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2000 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2001 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2004 |
4 organizations
Page 1 / 1